A synthetic peptide corresponding to residues in Human VIPR1.
Conjugation:
Unconjugated
Alternative Names:
Vasoactive intestinal polypeptide receptor 1, VIP-R-1, Pituitary adenylate cyclase-activating polypeptide type II receptor, PACAP type II receptor, PACAP-R-2, PACAP-R2, VPAC1, VIPR1
The vasoactive intestinal peptide (VIP) and pituitary adenylate cylase-activating polypeptide (PACAP) belong to a superfamily of peptide hormones that include glucagon, secretin and growth hormone releasing hormone (1,2). The effects of VIP and PACAP are mediated by three G-protein coupled receptors, VPAC1, VPAC2 and the PACAP receptor (also designated PAC1-R) (1,2). The VPAC receptors have equal affinities for VIP and PACAP, which stimulate the activation of adenylyl cyclase (1,3). Both VPAC1 and VPAC2 are abundantly expressed in brain and T cells, where they modulate neuronal differentiation and T cell activation, respectively (1,4-6). The PACAP receptor is a seven transmembrane protein that produces at least eight isoforms by alternative splicing (2). Each isoform is associated with a specific signaling pathway and a specific expression pattern (2). The PACAP receptor, which is thought to play an integral role in brain development, preferentially binds PACAP in order to stimulate a cAMP-protein kinase A signaling pathway (2,7).
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Form:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Application Dilute:
WB: 1:500~1:1000
Application Notes:
VIPR1 polyclonal antibody detects endogenous levels of VIPR1 protein.
* VAT and and shipping costs not included. Errors and price changes excepted
